{"id":"NCT04211363","sponsor":"Arcutis Biotherapeutics, Inc.","briefTitle":"Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis","officialTitle":"A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-12-20","primaryCompletion":"2020-11-16","completion":"2020-11-16","firstPosted":"2019-12-26","resultsPosted":"2022-11-03","lastUpdate":"2022-12-07"},"enrollment":439,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"Roflumilast 0.3% cream","otherNames":["ARQ-151"]},{"type":"DRUG","name":"Vehicle Cream","otherNames":[]}],"arms":[{"label":"Rofumilast Cream 0.3%","type":"EXPERIMENTAL"},{"label":"Vehicle cream","type":"PLACEBO_COMPARATOR"}],"summary":"This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.","primaryOutcome":{"measure":"Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8","timeFrame":"Baseline (Day 1) and Week 8","effectByArm":[{"arm":"Rofumilast Cream 0.3%","deltaMin":108,"sd":null},{"arm":"Vehicle Cream","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":40,"countries":["United States","Canada"]},"refs":{"pmids":["36422852","36125472"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":286},"commonTop":[]}}